当前位置: X-MOL 学术J. Ophthal. Inflamm. Infect. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis.
Journal of Ophthalmic Inflammation and Infection Pub Date : 2020-09-21 , DOI: 10.1186/s12348-020-00215-1
Scott Joseph Sonne 1 , Bradley Thomas Smith 2, 3
Affiliation  

Patients with multiple sclerosis (MS) have a higher incidence of uveitis compared with the general population. Fingolimod, a first line disease modifying drug used in multiple sclerosis, may cause macular edema and thus requires ophthalmic examination. However, murine models and anecdotal reports suggest fingolimod may reduce the incidence of uveitis. To report the incidence of uveitis and macular edema among those on fingolimod 0.5 mg (Gilenya®) therapy for multiple sclerosis (MS). Retrospective review of patients on fingolimod who developed uveitis and/or macular edema. No patients had an occurrence or history of uveitis. Four of the 188 (2.13%) patients developed macular edema without ocular inflammation. One of the 188 (0.53%) patients developed Acute Macular Neuroretinopathy. Patients taking fingolimod have a lower incidence of uveitis than expected in a population of MS patients.

中文翻译:

服用芬戈莫德0.5 mg的多发性硬化症患者葡萄膜炎和黄斑水肿的发生率。

与一般人群相比,多发性硬化症(MS)患者葡萄膜炎的发生率更高。芬戈莫德是一种用于多发性硬化症的一线疾病改良药物,可能引起黄斑水肿,因此需要进行眼科检查。但是,小鼠模型和轶事报告表明,芬戈莫德可以降低葡萄膜炎的发生率。报告使用芬戈莫德0.5 mg(Gilenya®)治疗多发性硬化症(MS)者中葡萄膜炎和黄斑水肿的发生率。芬戈莫德发生葡萄膜炎和/或黄斑水肿的患者的回顾性研究。没有患者发生葡萄膜炎或有葡萄膜炎病史。188名患者中有4名(2.13%)出现了黄斑水肿而没有眼部炎症。188名患者(0.53%)患上了急性黄斑神经视网膜病。
更新日期:2020-09-21
down
wechat
bug